12
Apr
2023
The Frontier of Epigenetic Editing: Chroma CEO Catherine Stehman-Breen
Today’s guest on The Long Run is Catherine Stehman-Breen. Catherine is the CEO of Boston-based Chroma Medicine. Chroma is working on therapies that control gene expression through epigenetic editing. People have heard a lot about editing of the genome with CRISPR, and then subsequent refinements of the technology known as base editing and prime editing. The question at Chroma is... Read More
12
Apr
2023
Function Gets $28M to Make Personalized Cancer Genomics to the Next Level
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.